35.46  -1.45 (-3.93%)		06-05 16:00
Open: 36.44 High: 36.44 Volume: 49,622		Pre. Close: 36.91 Low: 34.6 Market Cap: 1,794(M)

Short term
Mid term
Targets	6-month :	54.76	1-year :	66.73
Resists	First :	46.88	Second :	57.13
Pivot price	41.06
Supports	First :	30.29	Second :	25.2
MAs	MA(5) :	36.46	MA(20) :	43.51
	MA(100) :	31.97	MA(250) :	21.41
MACD	MACD :	-0.7	Signal :	0.7
%K %D	K(14,3) :	6	D(3) :	5
RSI	RSI(14): 41.5
52-week	High :	57.13	Low :	4.17

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NBTX ] has closed above bottom band by 19.8%. Bollinger Bands are 69.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 21 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	36.54 - 36.75	36.75 - 36.91
Low:	33.99 - 34.27	34.27 - 34.5
Close:	35.04 - 35.46	35.46 - 35.81

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Fri, 05 Jun 2026
Nanobiotix (NASDAQ: NBTX) details May 2026 voting rights update - Stock Titan

Fri, 05 Jun 2026
Nanobiotix lists 50.8M shares, 54.3M voting rights as of May 31 - Stock Titan

Thu, 04 Jun 2026
NBTX Maintained by Leerink Partners -- Price Target Raised to $4 - GuruFocus

Wed, 03 Jun 2026
NBTX Stock Price, Quote & Chart | NANOBIOTIX SA - ADR (NASDAQ:NBTX) - ChartMill

Tue, 02 Jun 2026
€86.1M raise extends Nanobiotix (NASDAQ: NBTX) cash runway into 2029 - Stock Titan

Tue, 02 Jun 2026
Lung cancer trial shows responses in 6 of 7 patients on Nanobiotix drug - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	51 (M)
Shares Float	32 (M)
Held by Insiders	0 (%)
Held by Institutions	11.7 (%)
Shares Short	80 (K)
Shares Short P.Month	11 (K)

EPS	-0.58
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-2.04
Profit Margin	-73.6 %
Operating Margin	-196.5 %
Return on Assets (ttm)	-10.1 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0.64
Sales Per Share	0.64
EBITDA (p.s.)	-0.21
Qtrly Earnings Growth	0 %
Operating Cash Flow	-33 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-61.14
PEG Ratio	0
Price to Book value	-17.39
Price to Sales	55.17
Price to Cash Flow	-53.81

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.